3-溴-5-甲氧基-1H-吡咯并[2,3-B]吡啶 | 1053655-76-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 3-溴-5-甲氧基-1H-吡咯并[2,3-B]吡啶
• 英文名称: 3-bromo-5-methoxy-1H-pyrrolo[2,3-b]pyridine
• CAS: 1053655-76-7
• 化学式: C₈H₇BrN₂O
• 分子量: 227.06
• InChiKey: ORLBCCYCMDWJEF-UHFFFAOYSA-N

物化性质

• 密度：
  1.678±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317

反应信息

• 作为反应物：
  描述：

  3-溴-5-甲氧基-1H-吡咯并[2,3-B]吡啶 、 对甲苯磺酰氯 在 碘 、 sodium hydride 、 锌 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.58h， 生成 tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-methoxy-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate
  参考文献：
  名称：

  Synthesis of Differentially Protected Azatryptophan Analogs via Pd₂(dba)₃/XPhos Catalyzed Negishi Coupling of N-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected tert-Butyl (R)-2-Amino-3-iodopropanoate

  摘要：

  Unnatural amino acids play an important role in peptide based drug discovery. Herein, we report a class of differentially protected azatryptophan derivatives synthesized from N-tosyl-3-haloazaindoles 1 and Fmoc-protected tert-butyl iodoalanine 2 via a Negishi coupling. Through ligand screening, Pd-2(dba)(3)/XPhos was found to be a superior catalyst for the coupling of 1 with the zinc derivative of 2 to give tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate derivatives 3 in 69-91% isolated yields. In addition, we have demonstrated that the protecting groups, namely, Ts, Fmoc, and Bu-t, can be easily removed selectively.

  DOI：

  10.1021/acs.joc.0c00973
• 作为产物：
  描述：

  5-甲氧基-7-氮杂吲哚 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 3-溴-5-甲氧基-1H-吡咯并[2,3-B]吡啶
  参考文献：
  名称：

  PYRROLOPYRIDINE INHIBITORS OF KINASES

  摘要：

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。

  公开号：

  US20110015173A1

文献信息

• Pyrrolopyridine inhibitors of kinases
  申请人：Florjancic Alan S.

  公开号：US08435980B2

  公开（公告）日：2013-05-07

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药物可接受的盐，其中R1a，R1b，R1c，X和Y在说明书中有定义。本发明还涉及含有所述化合物的组合物，该组合物对于抑制Cdc7等激酶以及治疗癌症等疾病的方法是有用的。
• Modulators of hedgehog (Hh) signaling pathway
  申请人：E-THERAPEUTICS PLC

  公开号：US10961238B2

  公开（公告）日：2021-03-30

  There are described compounds of formula (I): and there use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the of the hedgehog pathway, such as cancer, fibrosis and chronic graft-versus-host disease (cGVHD).

  所述的式 (I) 化合物可作为药物用于治疗涉及刺猬通路异常激活和/或功能失调的疾病，如癌症、纤维化和慢性移植物抗宿主病 (cGVHD)。
• US8435980B2
  申请人：——

  公开号：US8435980B2

  公开（公告）日：2013-05-07
• Synthesis of Differentially Protected Azatryptophan Analogs via Pd₂(dba)₃/XPhos Catalyzed Negishi Coupling of <i>N</i>-Ts Azaindole Halides with Zinc Derivative from Fmoc-Protected <i>tert</i>-Butyl (<i>R</i>)-2-Amino-3-iodopropanoate
  作者：Roshan Y Nimje、Devaiah Vytla、Prakasam Kuppusamy、Rajeswari Velayuthaperumal、Lokesh Babu Jarugu、China Anki Reddy、Nanjundaswamy Kanikahalli Chikkananjaiah、Richard A. Rampulla、Cullen L. Cavallaro、Jianqing Li、Arvind Mathur、Anuradha Gupta、Amrita Roy

  DOI：10.1021/acs.joc.0c00973

  日期：2020.9.4

  Unnatural amino acids play an important role in peptide based drug discovery. Herein, we report a class of differentially protected azatryptophan derivatives synthesized from N-tosyl-3-haloazaindoles 1 and Fmoc-protected tert-butyl iodoalanine 2 via a Negishi coupling. Through ligand screening, Pd-2(dba)(3)/XPhos was found to be a superior catalyst for the coupling of 1 with the zinc derivative of 2 to give tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate derivatives 3 in 69-91% isolated yields. In addition, we have demonstrated that the protecting groups, namely, Ts, Fmoc, and Bu-t, can be easily removed selectively.
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。